The Charcot-Marie-Tooth Association (CMTA) announced the addition of Patricia Verduin, PhD, an accomplished leader in the realms of science, technology, and sustainability, to its Board of Directors. Dr. Verduin comes with a rich background underscored by prestigious positions at FMC Corporation, Ingredion Corporation, and Monsanto, as well as Chief Science Officer at Colgate Palmolive. With her extensive experience in product innovation dedicated to global health and environmental well-being, she aims to contribute significantly to CMTA’s mission of enhancing lives and advancing research for treatments of Charcot-Marie-Tooth disease (CMT)—a rare neuromuscular disorder affecting one in 2,500 people, characterized by progressive muscle weakness and atrophy. CMTA, operating as a non-profit organization since 2008 and having invested over $24 million in CMT research, functions as the primary philanthropic entity spearheading advancements in CMT treatments and cures. CMTA’s leadership and community eagerly welcome Dr. Verduin’s expertise, expecting it to complement their ongoing endeavors to improve patient support and spearhead transformative research for the CMT community.

Non-Profit Organizations / Philanthropy, Healthcare / Biotechnology,Glenolden, Pennsylvania, United States